Biotech · Private company
Opna Bio LLC
Track this companyFree. Adds Opna Bio LLC to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Abiraterone acetatePhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Gynecologic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853Phase 2 · Gynecologic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853 20 mgPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853 40 mgPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853 80 mgPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 1 · Relapsed Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- OPN-6602Phase 1 · Relapsed Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853Phase 1 · Relapsed Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- PLX2853Phase 1 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaPHASE1 · RECRUITING · started Aug 22, 2024ClinicalTrials.gov NCT06433947 · fetched Nov 12, 2026
- PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)PHASE1_PHASE2 · TERMINATED · started Sep 21, 2020ClinicalTrials.gov NCT04556617 · fetched Nov 12, 2026
- PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian CancerPHASE1_PHASE2 · TERMINATED · started Aug 11, 2020ClinicalTrials.gov NCT04493619 · fetched Nov 12, 2026
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromePHASE1 · COMPLETED · started Mar 19, 2019ClinicalTrials.gov NCT03787498 · fetched Nov 12, 2026
- A Study of PLX2853 in Advanced Malignancies.PHASE1 · COMPLETED · started Sep 12, 2017ClinicalTrials.gov NCT03297424 · fetched Nov 12, 2026